Action B6E SWEDISH ORPHAN BIOVITRUM AB
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Swedish Orphan Biovitrum AB Xetra

Actions

B6E

SE0000872095

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance
Swedish Orphan Biovitrum AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
Swedish Orphan Biovitrum AB Updates Earnings Guidance for the Year 2024
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
Invitation: Sobi's Q2 2024 report
Sweden's Sobi Begins Rolling Application for Gout Treatment in US
Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout
Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout
Sobi Wins EU Approval for Hemophilia A Drug Altuvoct
European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A
Swedish Orphan Biovitrum : European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A
Swedish Orphan Biovitrum : Sobi to present new haemophilia data at ISTH 2024
Swedish Orphan Biovitrum : Sobi to present new data across its haematology portfolio at the 2024 EHA congress
BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome
Bulletin from Sobi's Annual General Meeting (AGM)
Swedish Orphan Biovitrum AB Elects Zlatko Rihter as New Board Member
Sobi Finalizes Inaugural SEK3 Billion Bond Issue
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action SOBI
  4. Action B6E
  5. Actualités Swedish Orphan Biovitrum AB
  6. Autres langues